AbbVie Inc.
ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS

Last updated:

Abstract:

The invention provides a stable formulation comprising an anti-EGFR antibody drug conjugate (ADC), including an anti-EGFR antibody, e.g., antibody 1, conjugated to an auristatin, e.g., MMAF, histidine, a sugar, and a surfactant.

Status:
Application
Type:

Utility

Filling date:

17 Oct 2019

Issue date:

10 Sep 2020